PAR 2.00% 24.5¢ paradigm biopharmaceuticals limited..

Paradigm Ip Patents/ Trademarks

  1. 300 Posts.
    lightbulb Created with Sketch. 38
    Paradigm engaged FB Rice in the development, registration and prosecution of our patents in order to secure a strong IP position. Paradigm has registered for the BME product Zilosul (tmr) and respiratory product Rhinosul (tmr) for Allergic Rhinitis.

    Paradigm’s patent coverages includes

    BME for treatment of bone marrow edema lesions with Pentosan Polysulphate covering Australia, USA, Japan, China, Taiwan, Singapore and other countries across the Asia Pacific

    MPS patented for treatment with Pentosan Polysulphate covering the same regions

    Alphavirus patented for treatment with Pentosan Polysulphate covering the same regions

    Respiratory Disease for treatment with Pentosan Polysulphate covering the same regions

    Trademarks - Paradigm has trademarked it's proprietary formulations for Pentosan Polysulphate Sodium for treatment of bone marrow edema - Zilosul and Rhinosul.

    Any other concerns, they have pretty well stitched it up IMHO
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.5¢
Change
-0.005(2.00%)
Mkt cap ! $85.7M
Open High Low Value Volume
25.0¢ 25.5¢ 24.5¢ $154.8K 626.6K

Buyers (Bids)

No. Vol. Price($)
2 35320 24.5¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 149065 5
View Market Depth
Last trade - 16.10pm 22/05/2024 (20 minute delay) ?
Last
24.5¢
  Change
-0.005 ( 1.88 %)
Open High Low Volume
25.5¢ 25.5¢ 24.5¢ 292562
Last updated 15.57pm 22/05/2024 ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.